Navigation Links
ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
Date:4/18/2011

LOS ANGELES, April 18, 2011 /PRNewswire/ -- ImaginAb, Inc. and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with Positron Emission Tomography (PET).

"We are pleased that ImaginAb has expanded its technology portfolio and recognized the cutting-edge work being developed by the Crump Institute," said Dr. Claire Wake, Director, at the university's Office of Intellectual Property and Industry Sponsored Research (OIP-ISR).

"UCLA is truly a world leader in technologies related to PET, from Molecular and Medical Pharmacology department chair Dr. Michael Phelps' pioneering of the field some thirty years ago to the incredible multi-disciplinary innovation occurring there today," said Dr. Christian Behrenbruch, CEO of ImaginAb. "This technology will become an important part of ImaginAb's strategy to combine the readily available and low-cost supply of F-18 from existing cyclotron networks with ImaginAb's rapid development of targeted molecular imaging agents based on antibody fragments and other small protein scaffolds."

The licensed technology originates from the UCLA's Crump Institute for Molecular Imaging through research sponsored by the U.S. Department of Energy. The agreement grants exclusivity to ImaginAb for antibodies and antibody fragments.

About ImaginAb

Founded in 2007 by UCLA faculty members Dr. Robert Reiter, Professor of Urology and Molecular Biology, Dr. Anna Wu, Professor, Molecular & Medical Pharmacology and then-faculty member Dr. Behrenbruch, ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
4. Energy technologies not enough to sufficiently reduce carbon emissions, NYUs Hoffert concludes
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
7. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
10. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
11. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the ... company combining a leading CRO and the industry’s only Contract Commercial Organization ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... Research and Markets has announced the addition of ... to their offering. ... , This report describes ... such as proteomics and metabolomics. Molecular diagnostics technologies are used for ... biomarker. Currently the most important applications of biomarkers are ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
Breaking Biology News(10 mins):